Latham & Watkins Advises Alpha Tau on Completed Business Combination with Healthcare Capital Corp.

deSPAC transaction created a publicly traded company focused on transforming the treatment of solid tumors through the precision delivery of alpha radiation.

March 08, 2022

Alpha Tau Medical Ltd. (Alpha Tau), the developer of the innovative alpha-radiation cancer therapy Alpha DaRTâ„¢, and Healthcare Capital Corp. (Nasdaq: HCCC) (HCCC), a special purpose acquisition company, have announced the successful closing of the previously announced business combination (the Business Combination). The combined company will continue to be led by Alpha Tau's existing management team. Alpha Tau's ordinary shares and warrants are expected to begin trading on Tuesday, March 8, 2022, on Nasdaq under the ticker symbols "DRTS" and "DRTSW," respectively.

Latham & Watkins LLP represented Alpha Tau in the deSPAC transaction with an M&A team led by New York partner Eyal Orgad and New York counsel Michael Vardanian, with New York associate Charles Shier, and a capital markets team led by London partner Joshua Kiernan and New York partner Nathan Ajiashvili, with London counsel Michael Rosenberg and New York associate Danny Shulman. Advice was provided on tax matters by Century City partner Pardis Zomorodi, with New York associate Sam Yang.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.